Pasar al contenido principal

Disección y promoción de inmunidad adaptativa específica frente al poliomavirus (BKV) para prevenir la infección viral tras el trasplante renal (proyecto BK-VAX)

PI22/01019

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

  • Donadeu, Laura|||0000-0002-5089-5047
  • Gómez-Ollés, Susana|||0000-0002-8935-7641
  • Casanova, Franc|||0000-0001-7427-1987
  • Torija, Alba
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Boada Pérez, Meritxell|||0000-0002-8774-8593
  • Kervella, Delphine|||0000-0001-8069-6105
  • Crespo, Elena
  • Carrera-Muñoz, Claudia
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Quintero, Jesús|||0000-0002-6456-9031
  • Muñoz, Marina
  • Agüero, Fernando
  • González-Costello, José|||0000-0002-7437-3630
  • Lladó, Laura|||0000-0002-3717-3306
  • Favà, Alexandre|||0000-0003-1664-6001
  • Cañas, Laura
  • de la Hoz-Caballero, María del Mar
  • Meneghini, Maria|||0000-0001-7307-923X
  • Torres, Irina B.|||0000-0003-3304-0810
  • Juvé, Mariona|||0000-0001-8431-3757
  • Hafkamp, Florianne
  • Vila, Marta|||0000-0001-9303-5189
  • González Robles, Alba
  • Buzón, Maria José|||0000-0003-4427-9413
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Zúñiga, José Miguel
  • Monforte, Víctor|||0000-0002-2918-7679
  • Sáez-Giménez, Berta|||0000-0002-9307-728X
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Pardo, Emma|||0000-0001-8703-5457
  • Martínez, Xavier
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

  • Kervella, Delphine|||0000-0001-8069-6105
  • Casanova Ferrer, Franc
  • Kotton, Camille N
  • Donadeu, Laura|||0000-0002-5089-5047
  • Kumar, Deepali|||0000-0003-1961-0477
  • Pineda, Silvia|||0000-0003-4017-1480
  • Crespo, Elena
  • Meneghini, Maria|||0000-0001-7307-923X
  • González-Costelo, José
  • García Romero, Elena|||0000-0003-4090-6571
  • Lladó, Laura|||0000-0002-3717-3306
  • Cachero, Alba|||0000-0002-0010-4534
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Torres, Irina B.|||0000-0003-3304-0810
  • Martínez Lacalle, Anna
  • Castañeda, Zaira|||0000-0001-7526-1078
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Giral, Magali|||0000-0001-7641-1592
  • Brouard, Sophie
  • Girardin, François R.
  • Villard, Jean
  • Budde, K.
  • Lefaucheur, Carmen
  • Loupy, Alexandre|||0000-0003-3388-7747
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard, Oriol|||0000-0001-9468-7920
The interferon gamma (IFN-γ) enzyme-linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and can identify at-risk transplant patients of CMV infection; however, its clinical implementation remains elusive. We developed a novel CMV-CMI risk-score based on the standardized T-SPOT.CMV assay against 2 CMV antigens (immediate-early protein 1 [IE-1] and 65 kDa phosphoprotein [pp65]), a biomarker predicting CMV infection, both high viral replication, and disease by performing a pooled analysis of 570 kidney transplants participating in different clinical trials and subsequently validating it in 146 consecutives solid organ transplants (SOT) in an interventional trial. By incorporating clinical variables into the CMV-CMI risk-score, we built an integrative prognostic system quantifying the risk of CMV infection (CMV-PrognosTIC score) using elastic net penalized regression analysis. In the pooled derivation cohort, whereas specific IE-1/pp65-specific CMV-CMI frequencies independently correlated with high risk of CMV infection (areas under the curve [AUCs]: 0.694, P < 0.0001; 0.719, P < 0.0001, respectively), by combining both responses, 3 CMV-CMI risk-scores appeared, accurately discriminating low-risk (LR) from intermediate-risk (IR) and high-risk (HR) patients (98.7% negative predictive value [NPV], 97.2% sensitivity). Its prospective implementation guiding decision-making in an independent SOT cohort confirmed the very high NPV and sensitivity identifying LR patients. By integrating type of preventive therapy, patient age, and donor (D) and recipient (R) CMV-serostatus to the CMV-CMI risk-score, we generated a global risk-prognostic model showing accurate discrimination and calibration in both derivation (AUC: 0.807) and validation cohorts (AUC: 0.719). Conclusion: We developed a robust CMV-PrognosTIC score to quantify the risk of CMV infection in SOT, which may be readily implemented in clinical transplantation to personalize CMV preventive therapies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).